Mandate

Vinge advises Oncopeptides in connection with a directed share issue

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 727 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank AB (publ), Cowen, DNB Markets, a part of DNB Bank ASA, Jefferies International Limited and Kempen & CO N.V.

Oncopeptides is a clinical development pharmaceutical company focused on conducting anti-cancer research to develop treatments for the benefit of patients. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun and Hampus Olsson.

Related

Vinge has advised Consolid on the establishment of Consolid Equity III

The fund held its final closing on June 2, 2025, having secured commitments from a diverse investor base that includes several leading institutional investors from Europe and North America, as well as established fund-of-funds. The fundraising was highly successful, with the fund significantly oversubscribed. Consolid Equity III has more than doubled its total commitments compared to its predecessor fund.
July 02, 2025

Vinge advises EQT VIII in connection with the divestment of Recover to Pangea AS

Recover is a leading Scandinavian property remediation specialist. Following EQT’s acquisition in 2020, Recover has invested in its digital capabilities while divesting non-core business units to sharpen focus on water, fire and other core property remediation services.
July 02, 2025

Vinge advises XPartners on its issuance of senior secured bonds

Vinge advises XPartners Samhällsbyggnad AB (“XPartners”) in connection with its SEK 3 billion issuance of senior secured bonds
July 02, 2025